Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tocainide: a new oral antiarrhythmic agent.

S P Kutalek, J Morganroth, L N Horowitz

    Annals of Internal Medicine
    |September 1, 1985
    PubMed
    Summary

    Tocainide is an oral antiarrhythmic drug effective for ventricular arrhythmias. It offers similar efficacy to other class I agents but has potential central nervous and gastrointestinal side effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A thorough electrocardiogram study of edoxaban, a novel factor Xa inhibitor.

    Journal of clinical pharmacology·2011
    Same author

    Effects of the selective alpha 1a-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controlled study.

    Clinical pharmacology and therapeutics·2010
    Same author

    Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval).

    Clinical pharmacology and therapeutics·2009
    Same author

    Cardiac repolarization and the safety of new drugs defined by electrocardiography.

    Clinical pharmacology and therapeutics·2006
    Same author

    Evaluation of the effect on cardiac repolarization (QTc interval) of oncologic drugs.

    Ernst Schering Research Foundation workshop·2006
    Same author

    Reprocessing of electrophysiology catheters: clinical studies, regulations, and recommendations. A report of the NASPE Task Force on Reprocessing of Electrophysiological Catheters. North American Society of Pacing and Electrophysiology.

    Pacing and clinical electrophysiology : PACE·2001

    Area of Science:

    • Pharmacology
    • Cardiology
    • Clinical Medicine

    Background:

    • Tocainide is a Class IB antiarrhythmic agent.
    • It possesses electrophysiologic properties similar to lidocaine.
    • Unlike lidocaine, tocainide is suitable for oral administration.

    Purpose of the Study:

    • To evaluate the efficacy and safety of tocainide.
    • To assess its utility in treating ventricular arrhythmias.
    • To characterize its pharmacokinetic and pharmacodynamic profile.

    Main Methods:

    • Investigational studies in animal models and human subjects.
    • Assessment of antiarrhythmic effectiveness in acute and chronic settings.
    • Evaluation of pharmacokinetic parameters like bioavailability and half-life.

    Main Results:

    • Tocainide demonstrated effectiveness in treating ventricular arrhythmias.
    • Oral bioavailability is nearly 100% with an effective half-life of 9-37 hours.
    • Common serious side effects include central nervous and gastrointestinal issues (10-20% of patients).

    Conclusions:

    • Tocainide is an orally effective Class IB antiarrhythmic agent.
    • Its efficacy is comparable to existing Class I antiarrhythmics.
    • Clinicians should monitor for potential central nervous and gastrointestinal adverse effects.

    Related Experiment Videos